MedTrace Logo

Effect of Genetic Polymorphism on Calcineurin Inhibitors Levels in Egyptian Renal Transplant Patients

NCT03830255 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 143

Last updated 2021-03-30

No results posted yet for this study

Summary

Renal transplantation is the treatment of choice for patients with end-stage renal disease (ESRD). Calcineurin Inhibitors tacrolimus and cyclosporine are the principle immunosuppressive agents administered to solid organ transplant recipients to prevent and treat allograft rejection.

The aim of the present study is to detect the incidence of some selected genetic polymorphism in Egyptian renal transplant population and investigate the influence of these genetic polymorphism (SNPs )on Cyclosporine and Tacrolimus blood concentration. In addition to detect the association between these genetic polymorphism variants and patients' clinical outcome after transplantation.

Conditions

  • Renal Transplantation

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Helwan University

    lead OTHER

Principal Investigators

  • Magdy El Sharkawy, MD · Ain Shams University

  • Abdel hameed Ibrahim Mohamed Ebid, PhD · Helwan University

  • Neama Lotfy, MD · Ain sham university

  • Mohamed Adel, PhD · Helwan University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2019-10-01
Completion
2020-03-29

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03830255 on ClinicalTrials.gov